What is it about?
In COPD patients without frequent exacerbations on long-term triple therapy (LAMA+LABA/ICS), the direct de-escalation to the once daily LABA/LAMA indacaterol/glycopyrronium led to a small decrease in lung function, with no difference in exacerbations in the majority of patients.
Featured Image
Read the Original
This page is a summary of: Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial, American Review of Respiratory Disease, August 2018, American Thoracic Society,
DOI: 10.1164/rccm.201803-0405oc.
You can read the full text:
Contributors
The following have contributed to this page
